New Stock News | It is reported that Siasun Robot & Automation company is considering an early listing in Hong Kong this year, with fundraising potentially reaching several billion US dollars.
The Chinese robotics startup company Linkerbot, which focuses on researching and developing high dexterity robotic arms, is reportedly considering conducting its initial public offering (IPO) in Hong Kong.
Chinese startup Siasun Robot & Automation, which focuses on developing high dexterity robotic arms, is reportedly considering conducting its initial public offering (IPO) in Hong Kong. Reports indicate that Linkerbot has hired CICC, CITIC SEC, and HSBC to arrange for a potential stock sale as early as this year. Discussions are ongoing, and some sources suggest that if the plan moves forward, Linkerbot could raise hundreds of millions of dollars through the listing.
Linkerbot stated this month that it aims to achieve a valuation of $6 billion (HK$46.8 billion) in its next round of funding, which is double the valuation from its previous round of financing where it reached $3 billion.
Early investors in Linkerbot include Ant Group, a subsidiary of Alibaba, and Redpoint China. As for the latest round of fundraising, state-backed entities Beijing Centergate Technologies, Bank of China Asset Management, and Fosun Chuangfu were involved.
Public information reveals that Linkerbot focuses on agile robotic arms and cloud intelligence technology, driving the development of the 2B and 2C markets through its intelligent platform. The company offers the exceptional LinkerHand product, providing innovative and efficient automation solutions to users worldwide.
Related Articles

COUNTRY GARDEN (02007) issued 122 million shares of zero-interest mandatory convertible bonds for conversion.

In the first quarter of the company, the profit attributable to owners decreased by 68.1% to HK$2.9 million.

Zhejiang Tianyu Pharmaceutical (300702.SZ): Gliclazide tablets obtained drug registration certificate
COUNTRY GARDEN (02007) issued 122 million shares of zero-interest mandatory convertible bonds for conversion.

In the first quarter of the company, the profit attributable to owners decreased by 68.1% to HK$2.9 million.

Zhejiang Tianyu Pharmaceutical (300702.SZ): Gliclazide tablets obtained drug registration certificate






